Keywords
Neurology
Mechanism of action
Enzymes
Submitted : 2024-04-09
Accepted : 2024-04-24
Published : 2024-05-09
Abstract
Enzyme inhibition therapy uses specific molecules to inhibit enzyme activity, targeting disease-related enzymes in medical treatments like cancer treatment and infectious disease management. Different types of inhibitors, competitive and non-competitive, bind to different sites and alter enzyme function. The success of this therapy depends on the inhibitor's specificity and delivery to the target site. Further research could lead to more effective treatments. Nowadays, the majority of medications are enzyme inhibitors and are in the clinical or pre-clinical stages of drug development. Enzyme inhibitors are often prescribed medications for a variety of illnesses, including neurological problems. There is only symptomatic therapy available for many neurological conditions, particularly neuro-degenerative disorders, as opposed to therapy based on knowledge of the underlying mechanisms of these diseases. Enzyme inhibitors are useful as they block the function of certain enzymes whose aberrant activity could be contributing to the illness. They also alleviate the symptoms and stop the disease’s progression. This review discusses the mechanism of action of several enzyme inhibitors that have been prescribed as medications for neurological illnesses as well as some that are still in research stages.
References
Sharma R, 2012, Enzyme Inhibition: Mechanisms and Scope. Enzyme Inhibition and Bioapplications, InTech, 10.5772/39273.
Mohan C Long KD Mutneja M, 2013, An Introduction to Inhibitors and Their Biological Applications. EMD Millipore Corp, 2013: 3–13.
Copeland RA, Harpel MR, Tummino PJ, 2007, Targeting Enzyme Inhibitors in Drug Discovery. Expert Opinion on Therapeutic Targets, 11(7): 967–978.
Kanwar JR, Sriramoju B, Kanwar RK, 2012, Neurological Disorders and Therapeutics Targeted to Surmount the Blood–Brain Barrier. International Journal of Nanomedicine. 7: 3259–3278.
Lleo A, Greenberg SM, Growdon JH, 2006, Current Pharmacotherapy for Alzheimer’s Disease. Annu Rev Med, 57: 513–533.
Gonçalves S, Romano A, 2017, Inhibitory Properties of Phenolic Compounds Against Enzymes Linked with Human Diseases. Phenolic Compounds-Biological Activity, InTech.
Finberg JP, 2010, Pharmacology of Rasagiline, A New MAO-B Inhibitor Drug for The Treatment of Parkinson’s Disease with Neuroprotective Potential. Rambam Maimonides Medical Journal, 1(1): e0003.
Perez-Lloret S, Rascol O, 2011, Safety of Rasagiline for The Treatment of Parkinson’s Disease. Expert Opinion on Drug Safety, 10(4): 633–643.
Finberg JPM, Rabey JM, 2016, Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Frontiers in Pharmacology, 7: 340.
Aronson JK, (ed) 2016, Meyler’s Side Effects of Drugs, The International Encyclopedia of Adverse Drug Reactions and Interactions, Elsevier, Netherlands, 338–339.
Ansara AJ, Nisly SA, Arif SA, et al., 2010, Aspirin Dosing for The Prevention and Treatment of Ischemic Stroke: An Indication-Specific Review of The Literature. Annals of Pharmacotherapy, 44(5): 851–862.
Lights V, 2022, Understanding Brain Tumors, Healthline, viewed 7 December, 2018, https://www.healthline.com/health/brain-tumor
New Drug Approvals, n.d., Prinomastat, viewed 7 December, 2018, https://newdrugapprovals.org/2014/03/25/prinomastat/
Zhao W, Qiu Y, Kong D, 2017, Class I Phosphatidylinositol 3-Kinase Inhibitors for Cancer Therapy. Acta Pharmaceutica Sinica B, 7(1): 27–37.
Tremont-Lukats IW, Gilbert MR, 2003, Advances in Molecular Therapies in Patients with Brain Tumors. Cancer Control, 10(2): 125–137.
American Brain Tumor Association, n.d., Glioblastoma (GBM), viewed 7 December, 2018, https://www.abta.org/tumor_types/glioblastoma-gbm/
American Association of Neurological Symptoms, n.d., Glioblastoma Multiforme, viewed 7 December, 2018, https://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme
Lau D, Magill ST, Aghi MK, 2014, Molecularly Targeted Therapies for Recurrent Glioblastoma: Current and Future Targets. Neurosurgical Focus, 37(6): E15.
Faraco G, Cavone L, Chiarugi A, 2011, The Therapeutic Potential of HDAC Inhibitors in The Treatment of Multiple Sclerosis. Molecular Medicine, 17(5–6): 442–447.
Dietz KC, Casaccia P, 2010, HDAC Inhibitors and Neurodegeneration: At the Edge Between Protection and Damage. Pharmacological Research, 62(1): 11–17.
Rajput MS, 2010, Natural Monoamine Oxidase Inhibitors: A Review. J Pharmacy Res, 3: 482–485.
Babitha KV, Shanmuga Sundaram R, Annapandian VM, et al., 2014, Natural Products and Its Derived Drugs for The Treatment of Neurodegenerative Disorders: Alzheimer’s Disease–A Review. British Biomedical Bulletin, 2: 359–370.
Suganthy N, Karutha P, Pandima D, 2009, Cholinesterase Inhibitors from Plants: Possible Treatment Strategy for Neurological Disorders-A Review. International Journal of Biomedicine and Pharmaceutical Sciences, 3: 87–103.
Khatri DK, Juvekar AR, 2016, Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid. Pharmacognosy Magazine, 12(Suppl 2): 116–120.
F Nabavi S, Daglia M, D’Antona G, et al., 2015, Natural Compounds Used as Therapies Targeting Amyotrophic Lateral Sclerosis. Current Pharmaceutical Biotechnology, 16(3): 211–218.
Kim JY, Park J, Lee JE, et al., 2017, NOX Inhibitors- ? Promising Avenue for Ischemic Stroke. Experimental Neurobiology, 26(4): 195–205.
Mojaverrostami S, Bojnordi MN, Ghasemi-Kasman M, et al., A Review of Herbal Therapy in Multiple Sclerosis, Adv Pharm Bull, 8(4): 575–590.
Kumar GP, Anilakumar KR, Naveen S, 2015, Phytochemicals Having Neuroprotective Properties from Dietary Sources and Medicinal Herbs. Pharmacognosy Journal. 7(1): 1–17.
Zarmouh NO, Messeha SS, Elshami FM, et al., 2016, Natural Products Screening for The Identification of Selective Monoamine Oxidase-B Inhibitors. European Journal of Medicinal Plants, 15(1): 14802.
Singhal AK, Naithani V, Bangar OP, 2012, Medicinal Plants with A Potential to Treat Alzheimer’s and Associated Symptoms. International Journal of Nutrition, Pharmacology, Neurological Diseases, 2(2): 84.
Murray AP, Faraoni MB, Castro MJ, et al., 2013, Natural AChE Inhibitors from Plants and Their Contribution to Alzheimer’s Disease Therapy. Current Neuropharmacology, 11(4): 388–413.
Mazzio E, Deiab S, Park K, et al., 2013, High Throughput Screening to Identify Natural Human Monoamine Oxidase B Inhibitors. Phytotherapy Research, 27(6): 818–828.
Erdogan Orhan I, 2016, Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors. Current Pharmaceutical Design, 22(3): 268–276.
Viña D, Serra S, Lamela M, et al., 2012, Herbal Natural Products as A Source of Monoamine Oxidase Inhibitors: A Review. Current Topics in Medicinal Chemistry, 12(20): 2131–2144.
Passos CD, Simoes-Pires C, Henriques A, et al., 2014, Alkaloids as Inhibitors of Monoamine Oxidases and Their Role in The Central Nervous System. Studies in Natural Products Chemistry, Elsevier, 43: 123–144.
Ong WY, Farooqui T, Kokotos G, et al., 2015, Synthetic and Natural Inhibitors of Phospholipases A2: Their Importance for Understanding and Treatment of Neurological Disorders. ACS Chemical Neuroscience, 6(6): 814–831.
Neumann U, Ufer M, Jacobson LH, et al., 2018, The BACE?1 Inhibitor CNP520 for Prevention Trials in Alzheimer’s Disease. EMBO Molecular Medicine, 10(11): e9316.
Barten DM, Meredith JE, Zaczek R, et al., 2006, ?-Secretase Inhibitors for Alzheimer’s Disease. Drugs in R&D, 7(2): 87–97.
Chopra V, Quinti L, Kim J, et al., 2012, The Sirtuin 2 Inhibitor AK-7 is Neuroprotective in Huntington’s Disease Mouse Models. Cell reports, 2(6): 1492–1497.
Quinti L, Casale M, Moniot S, et al., 2016, SIRT2-and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington’s Disease Models. Cell Chemical Biology, 23(7): 849–861.
Allocati N, Masulli M, Di Ilio C, et al., 2018, Glutathione Transferases: Substrates, Inhibitors, and Pro-Drugs in Cancer and Neurodegenerative Diseases. Oncogenesis, 7(1): 8.
Al-Badri G, Leggio GM, Musumeci G, et al., 2018, Tackling dipeptidyl Peptidase IV in Neurological Disorders. Neural Regeneration Research, 13(1): 26.
Solesio ME, Peixoto PM, Debure L, et al., 2018, Carbonic Anhydrase Inhibition Selectively Prevents Amyloid ? Neurovascular Mitochondrial Toxicity. Aging Cell, 17(4): e12787.
Supuran CT, Scozzafava A, 2000, Carbonic Anhydrase Inhibitors and Their Therapeutic Potential. Expert Opinion on Therapeutic Patents, 10(5): 575–600.
Madigan NN, Staff NP, Windebank AJ, et al., 2017, Genome Editing Technologies and Their Potential to Treat Neurologic Disease. Neurology, 89(16): 1739–1748.
Walters BJ, Azam AB, Gillon CJ, et al., 2016, Advanced in vivo use of CRISPR/Cas9 and anti-sense DNA Inhibition for Gene Manipulation in The Brain. Frontiers in Genetics, 6: 362.
White MK, Kaminski R, Wollebo H, et al., 2016, Gene Editing for Treatment of Neurological Infections. Neurotherapeutics, 13(3): 547–554.
Ostick J, 2017, CRISPR for Gene Editing in Neuroscience and Neurological Disease. ACNR, 18: 9–10.
Raikwar SP, Thangavel R, Dubova I, et al., 2018, Neuro-Immuno-Gene-and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet? Journal of Alzheimer’s Disease, 65(2): 321–344.
Vesikansa A, 2018, Unraveling of Central Nervous System Disease Mechanisms Using CRISPR Genome Manipulation. Journal of Central Nervous System Disease, 10: 1179573518787469
Khan S, Mahmood MS, ur Rahman S, et al., 2018, CRISPR/Cas9: the Jedi Against the Dark Empire of Diseases. Journal of Biomedical Science, 25(29).
Sun J, Carlson-Stevermer J, Das U, et al., 2018, A CRISPR/Cas9 Based Strategy to Manipulate The Alzheimer’s Amyloid Pathway. bioRxiv, 1: 310193.
Kramer NJ, Haney MS, Morgens DW, et al., 2018, CRISPR–Cas9 Screens in Human Cells and Primary Neurons Identify Modifiers of C9ORF72 Dipeptide-Repeat-Protein Toxicity. Nature Genetics, 50(4): 603.